Haleon , the world's biggest standalone consumer health business with brands such as Sensodyne toothpaste and Advil painkillers, reported its first full-year results on Thursday which analysts said were in line with expectations.
"Our organic revenue growth ... was well balanced between volume and price, with two thirds of the business gaining or holding share," McNamara said.reported organic revenue growth of 9% last year, just ahead of the 8-8.5% increase it predicted for 2022.
Haleon's respiratory health unit saw organic growth of 32.6% to 1.6 billion pounds in 2022, helped by a strong cold and flu season with sales significantly above 2019 levels in North America and Europe in the fourth quarter, the company said. Respiratory viruses have returned with a vengeance in the Northern hemisphere in the first winter free of COVID-19 restrictions since the start of the pandemic.
On Thursday, Haleon affirmed its medium term guidance, saying it expects to incur 150 million pounds in restructuring costs in 2023 and 2024 to generate savings of about 300 million pounds over the next three years. As of December, Haleon cut its debt to about 9.9 billion pounds, from roughly 10.7 billion pounds three months earlier.Our Standards:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer, GSK face FDA panel review in race for RSV vaccinesThe frontrunners in a crowded race to develop the first respiratory syncytial virus (RSV) vaccine - Pfizer Inc and GSK - will face scrutiny from a panel of experts to the U.S. Food and Drug Administration this week.
Read more »
US panel backs GSK vaccine, heating up RSV vaccine raceA panel of outside advisers to the U.S. health regulator on Wednesday backed GSK Plc's respiratory syncytial virus (RSV) vaccine, setting it up for a race with rival Pfizer to become the first approved U.S. shot against the disease.
Read more »
FDA Advisors Recommend GSK's RSV Vaccine for Older Adults, But Flag Potential Safety RisksA majority of the FDA panel said GlaxoSmithKline's RSV vaccine safety data was adequate and advisors were unanimous that the shot’s efficacy was good But some expressed concern that the shots could be associated with risks of rare nervous system disorders
Read more »
The race to an RSV vaccine is nearly over, decades after the first attemptIn two votes this week, an FDA advisory committee will decide whether to recommend RSV vaccines from Pfizer and GSK for older adults.
Read more »
FDA Considers Two Drugmakers for First RSV VaccineAn FDA advisory panel is considering two drugmakers to make the first respiratory syncytial virus (RSV) vaccine. Pfizer and GSK seek to lead the market that could be worth between $5 billion and $10 billion.
Read more »
Paving the way for the world's first RSV vaccine, FDA advisers recommend shot from PfizerBREAKING: FDA advisers recommend that the agency approve the country’s first RSV vaccine for older people, a shot from Pfizer for adults ages 60 and up.
Read more »